Edition:
United Kingdom

Aerie Pharmaceuticals Inc (AERI.OQ)

AERI.OQ on NASDAQ Stock Exchange Global Market

59.00USD
15 Dec 2017
Change (% chg)

$-1.15 (-1.91%)
Prev Close
$60.15
Open
$60.30
Day's High
$61.05
Day's Low
$58.90
Volume
229,702
Avg. Vol
169,800
52-wk High
$66.55
52-wk Low
$35.50

Select another date:

Mon, Dec 4 2017

BRIEF-Aerie Pharmaceuticals Appoints Heather Johnson As Regional Sales Director For Northeast Region

* AERIE PHARMACEUTICALS ANNOUNCES APPOINTMENT OF HEATHER JOHNSON AS REGIONAL SALES DIRECTOR FOR THE NORTHEAST REGION Source text for Eikon: Further company coverage:

BRIEF-Aerie Pharmaceuticals announces appointment Of Nhi Ong director of analytics

* AERIE PHARMACEUTICALS ANNOUNCES APPOINTMENT OF NHI ONG AS DIRECTOR OF ANALYTICS Source text for Eikon: Further company coverage:

BRIEF-Aerie Pharma initiates netarsudil ophthalmic solution Phase 2 clinical trial

* Aerie Pharmaceuticals initiates netarsudil ophthalmic solution Phase 2 clinical trial designed to meet requirements of regulatory filing in Japan

BRIEF-Aerie Pharmaceuticals Q3 loss per share $0.89

* Aerie Pharmaceuticals reports third quarter 2017 financial results and provides business update

BRIEF-Aerie Pharmaceuticals appoints John Maltman as vice president of medical affairs

* Aerie Pharmaceuticals announces appointment of John Maltman, PH.D., as vice president of medical affairs Source text for Eikon: Further company coverage:

BRIEF-Aerie Pharmaceuticals announces FDA advisory committee vote in favor of Rhopressa

* Aerie Pharmaceuticals announces FDA advisory committee vote in favor of Rhopressa (netarsudil ophthalmic solution) 0.02%

U.S. FDA panel backs Aerie's glaucoma drug Rhopressa

Aerie Pharmaceuticals Inc's experimental glaucoma treatment should be approved, an advisory committee to the U.S. Food and Drug Administration said on Friday, after it found the benefits outweigh the risks.

UPDATE 1-U.S. FDA panel backs Aerie's glaucoma drug Rhopressa

Oct 13 Aerie Pharmaceuticals Inc's experimental glaucoma treatment should be approved, an advisory committee to the U.S. Food and Drug Administration said on Friday, after it found the benefits outweigh the risks.

Aerie's glaucoma drug Rhopressa wins backing from U.S. FDA panel

Oct 13 The benefit of Aerie Pharmaceuticals Inc's experimental glaucoma treatment outweighs the risks and the drug should be approved, an advisory committee to the U.S. Food and Drug Administration concluded on Friday.

BRIEF-Aerie Pharmaceuticals says ‍FDA committee to review NDA for Rhopressa

* Aerie Pharmaceuticals Inc - ‍FDA advisory committee to review new drug application for Rhopressa (netarsudil ophthalmic solution) 0.02 pct​ Source text for Eikon: Further company coverage:

Select another date: